GLP-1 Side Effects: What New Research Reveals

As GLP-1 receptor agonists continue to reshape the treatment of type 2 diabetes and obesity, a critical question has emerged for both clinicians and patients: how manageable are the side effects that cause so many people to stop treatment before seeing meaningful results? A 2026 narrative expert review published in Nutrition in Clinical Practice offers one of the most comprehensive assessments to date, synthesizing evidence from randomized controlled trials, observational studies, meta-analyses, and pharmacovigilance data to characterize the gastrointestinal (GI) adverse effects associated with this rapidly expanding class of therapies (Singhani et al., 2026).

What This Study Found

The review by Singhani, Ehsan, Valencia, and colleagues examined approved GLP-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists (GIP/GLP-1 RAs), as well as several late-stage pipeline agents including retatrutide, survodutide, and cagrilintide-semaglutide. The researchers found that nausea, vomiting, diarrhea, and constipation are established class effects, occurring in approximately 30% to 50% of patients, most frequently during the initiation and dose-escalation phases of treatment.

Importantly, the study suggests these GI events are generally mild to moderate in severity and tend to be manageable with careful dose titration and dietary modification — a finding with significant implications for how clinicians guide patients through the early weeks of therapy.

The researchers identified several mechanisms believed to drive these GI effects. These include delayed gastric emptying, central activation of emetic pathways in the brain, altered intestinal motility, and physiologic effects associated with rapid weight loss itself. This last point is noteworthy: some GI symptoms may not be purely a pharmacological effect of the drug, but rather a downstream consequence of the metabolic changes the drug is designed to produce.

On the question of more serious GI complications, the review offers some reassurance. Regarding acute pancreatitis — a concern that has long shadowed this drug class — the study suggests that randomized trial data show no class-level excess risk. The researchers note that pharmacovigilance signals that have appeared in post-market surveillance are most plausibly explained by diagnostic misclassification rather than a true causal relationship between the drugs and pancreatitis.

Cholelithiasis (gallstone formation) presents a more nuanced picture. The researchers found a probable class-level association with gallstone development, but suggest this risk is substantially mediated by weight loss itself rather than by direct receptor signaling — meaning the gallstone risk may be an indirect consequence of the very weight reduction these therapies are designed to achieve, rather than a specific toxicity of the drugs.

The review also addresses peri-procedural safety, noting that data show increased residual gastric volume in patients using these medications — a relevant concern for patients undergoing anesthesia. However, the researchers found no confirmed aspiration events in the available data, suggesting that while vigilance is warranted, the clinical risk in this context remains to be more fully characterized.

For pipeline agents, preliminary data suggest a similar GI adverse event profile to currently approved therapies, though the researchers caution that evidence for these newer molecules remains largely limited at this stage.

Clinical Significance

The clinical implications of this review are substantial. GI adverse events are identified as the leading cause of discontinuation among patients using GLP-1-based therapies — a critical problem given that these medications require sustained use to deliver their full metabolic and cardiovascular benefits. When patients stop treatment due to nausea or vomiting in the first few weeks, they may be abandoning a therapy that could have offered meaningful long-term health improvements.

The study suggests that a proactive, patient-centered approach is essential. This means anticipating GI side effects before they occur, counseling patients that early symptoms are typically temporary and dose-dependent, and having a structured plan for dose titration that minimizes discomfort while still progressing toward a therapeutic target dose.

Dietary guidance also plays a meaningful role. The researchers emphasize that modifications to meal size, composition, and eating pace can help reduce the severity of nausea and other GI complaints. Clinicians working with patients on these therapies should ideally incorporate nutritional counseling as a standard component of care, not an afterthought.

The review also highlights the importance of distinguishing between GI symptoms that are expected and self-limiting versus those that may signal a more serious complication. While the data on pancreatitis are reassuring at the class level, individual patients with abdominal pain that is severe or persistent should still receive appropriate clinical evaluation.

Current Access and Compliance Context

Understanding GI side effects is not only a clinical issue — it is increasingly an access and adherence issue. As demand for GLP-1 and GIP/GLP-1 receptor agonists has surged, patients are navigating a complex landscape that includes insurance coverage limitations, compounded formulations, and a growing pipeline of new agents. In this environment, side effect management has become a key determinant of whether patients successfully complete an adequate course of therapy.

The expansion of oral formulations for some agents in this class adds another dimension to the GI side effect conversation. Oral GLP-1 RAs interact with the GI tract in ways that differ from injectable formulations, and the review acknowledges this as an area where the evidence base continues to develop. Patients and providers selecting between formulations should consider not only convenience but also the specific GI tolerability profile associated with each route of administration.

As newer pipeline agents reach approval and broader clinical use, the findings of this review suggest that the GI side effect burden is unlikely to disappear — but that it remains predictable and manageable with the right clinical infrastructure in place.

What Patients Should Know

If you are currently taking or considering a GLP-1 receptor agonist or a dual GIP/GLP-1 receptor agonist, the research suggests several important takeaways:

• GI side effects are common but often temporary. Nausea, vomiting, diarrhea, and constipation affect a significant proportion of patients, particularly in the early weeks of treatment, but the study suggests these symptoms are generally mild to moderate and tend to improve over time.
• How you start the medication matters. Slow dose escalation and dietary adjustments are among the most evidence-supported strategies for reducing GI discomfort.
• Serious GI risks appear to be lower than feared. Based on randomized trial data reviewed by the researchers, acute pancreatitis does not appear to be a class-level risk, though patients should always discuss personal risk factors with their provider.
• Gallstone risk deserves attention. The study suggests a probable association between these therapies and cholelithiasis, largely tied to weight loss itself. Patients should discuss this risk with their healthcare provider, particularly if they have other gallstone risk factors.
• Do not discontinue without speaking to your provider. Given that GI side effects are a leading cause of early discontinuation, it is worth communicating openly with your care team before stopping treatment — there may be dose adjustments or supportive strategies that can help.

Conclusion

The 2026 expert review by Singhani and colleagues provides a comprehensive, evidence-grounded framework for understanding the GI adverse effects of GLP-1-based therapies. The study suggests that while these side effects are among the most common limitations of the drug class, they are largely predictable, mechanistically understood, and manageable with a proactive clinical approach. As the therapeutic landscape continues to expand with new agents and formulations, the principles outlined in this review — careful titration, dietary guidance, patient education, and individualized monitoring — will remain foundational to optimizing outcomes.

If you are seeking guidance on peptide-based therapies and want to connect with a knowledgeable healthcare provider, the Peptide Association can help. Visit peptideassociation.org/find-a-doctor to find a qualified clinician in your area who can provide personalized, evidence-informed care.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented reflects findings from a published scientific review and should not be used as a substitute for consultation with a qualified healthcare provider. Always speak with your physician or other licensed health professional before starting, stopping, or modifying any medication or treatment regimen.

---

Citation: Singhani V, Ehsan M, Valencia S, et al. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents. Nutrition in Clinical Practice: Official Publication of the American Society for Parenteral and Enteral Nutrition. 2026. doi:10.1002/ncp.70180. PMID: 42808923.